A Randomized Study to Evaluate the Effect of an Inclisiran First Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 450 participants.
Also called NCT04929249
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 450 participants
- Sponsor
- Registry
-
NCT04929249
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04929249. Randomized; no masking; primary purpose treatment. Start 2021-06-25 (actual); primary completion 2023-09-15 (actual). Results posted on 2024-09-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
- Acronym
- V-INITIATE
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Inclisiran
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct04929249- Content hash
e35f93d3f613520a9a4e5edb9f5bcf4f41ebfd3a997e51313220841392273cba